S

Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294

Watchlist Manager
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Watchlist
Price: 59.08 CNY -3.31%
Market Cap: 65.9B CNY

Relative Value

The Relative Value of one Shenzhen Salubris Pharmaceuticals Co Ltd stock under the Base Case scenario is 32.45 CNY. Compared to the current market price of 59.08 CNY, Shenzhen Salubris Pharmaceuticals Co Ltd is Overvalued by 45%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
32.45 CNY
Overvaluation 45%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
0
vs Industry
16
Median 3Y
9.9
Median 5Y
10.1
Industry
2.6
Forward
14.5
vs History
22
vs Industry
8
Median 3Y
60.6
Median 5Y
61.2
Industry
21.7
Forward
92.8
vs History
0
vs Industry
15
Median 3Y
37.5
Median 5Y
33.7
Industry
16.6
vs History
14
vs Industry
7
Median 3Y
134.4
Median 5Y
89.6
Industry
22.5
vs History
0
vs Industry
19
Median 3Y
4.5
Median 5Y
4.4
Industry
2.3
vs History
0
vs Industry
16
Median 3Y
9.8
Median 5Y
9.6
Industry
2.9
Forward
13.9
vs History
0
vs Industry
19
Median 3Y
14
Median 5Y
13.8
Industry
5.5
vs History
14
vs Industry
6
Median 3Y
58.1
Median 5Y
60.5
Industry
13.1
Forward
73.9
vs History
14
vs Industry
7
Median 3Y
58.1
Median 5Y
60.5
Industry
16.6
Forward
85.7
vs History
0
vs Industry
16
Median 3Y
36.7
Median 5Y
32.3
Industry
15.8
vs History
4
vs Industry
9
Median 3Y
102.3
Median 5Y
88.6
Industry
19.1
vs History
0
vs Industry
21
Median 3Y
4.4
Median 5Y
4.4
Industry
1.9

Multiples Across Competitors

Competitors Multiples
Shenzhen Salubris Pharmaceuticals Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
65.9B CNY 15.5 97.9 99.8 99.8
US
Eli Lilly and Co
NYSE:LLY
939.8B USD 15.8 51 34.3 36.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
497B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
256.4B CHF 4.2 27.2 11.6 13.6
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 4.8 29.8 108.8 159.3
CH
Novartis AG
SIX:NOVN
202.3B CHF 4.5 17.6 11.2 14.4
US
Merck & Co Inc
NYSE:MRK
242.8B USD 3.8 12.8 9.1 10.8
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.2 9.3 10.8
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
146.6B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
CN
S
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Average P/E: 31.6
97.9
18%
5.4
US
Eli Lilly and Co
NYSE:LLY
51
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.2
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.8
38%
0.8
CH
Novartis AG
SIX:NOVN
17.6
17%
1
US
Merck & Co Inc
NYSE:MRK
12.8
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
S
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Average EV/EBITDA: 406.9
99.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.3
33%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.6
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.1
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
S
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Average EV/EBIT: 1 716.8
99.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.8
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.6
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
159.3
23%
6.9
CH
Novartis AG
SIX:NOVN
14.4
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.8
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3